Krystal Biotech, Inc. Common Stock

KRYSNASDAQUSD
359.93 USD
12.30 (3.54%)AT CLOSE (11:59 AM EDT)
361.56
1.63 (0.45%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
361.56
1.63 (0.45%)
🔴Market: CLOSED

Shares of Krystal Biotech, Inc. Common Stock (KRYS) are trading at $359.88. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, KRYS is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jun 25, 2026.

Open?$347.27
High?$362.40
Low?$347.21
Prev. Close?$347.63
Volume?329.9K
Avg. Volume?301.8K
VWAP?$356.50
Rel. Volume?1.09x
Bid / Ask
Bid?$352.00 × 40
Ask?$371.13 × 200
Spread?$19.13
Midpoint?$361.57
Valuation & Ratios
Market Cap?10.6B
Shares Out?29.5M
Float?23.9M
Float %?81.3%
P/E Ratio?47.15
P/B Ratio?8.31
EPS?$7.63
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Employees
295
Market Cap
10.2B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2017-09-20
Address
2100 WHARTON STREET
PITTSBURGH, PA 15203
Phone: (412) 586-5830
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Bullish(+3/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
83
Short Sent.?
28
Piotroski F-Score?4/9Mixed
Altman Z-Score?52.72Safe
Confidence?61%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?13.11%High
Short Interest?3.1M
Days to Cover?10.9
Free Float23.9M
Avg Daily Volume288.9K
Settlement Date2026-06-15
Financial Health
Current Ratio?9.46Strong
Quick Ratio?9.06Strong
Cash Ratio?4.65Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
33/100
P/E?
Peers
100
S&P
14
47.2PRICEY
P/B?
Peers
100
S&P
23
8.31HIGH
P/S?
Peers
100
S&P
3
25.43HIGH
P/FCF?
Peers
100
S&P
14
44.7PRICEY
EV/EBITDA?
Peers
100
S&P
3
54.8HIGH
EV/Sales?
Peers
100
S&P
3
24.23HIGH
Returns & Efficiency
ROE?
Peers
50
S&P
61
17.6%STRONG
ROA?
Peers
50
S&P
89
16.1%STRONG
Cash Flow & Enterprise
FCF?$237.4M
Enterprise Value?$10.1B
Fundamentals ratios updated end of day